Zura Bio Ltd(ZURA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ZURA Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Zura Bio Ltd (ZURA), a Healthcare sector company. ZURA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Zura Bio Ltd reports net income of $-26.3M, free cash flow of $18.9M. Top institutional holders of ZURA by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT, VR Adviser, MPM BioImpact, based on the most recent SEC filings. ZURA trades on the Nasdaq exchange and files with the SEC under CIK 1855644. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZURA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Zura Bio Ltd directly from SEC EDGAR.
Net Income
Q2 2026
$-26.3M
Free Cash Flow
Q2 2026
$18.9M
ROIC
Q2 2026
-59.5%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-31.0% YoYOperating Income
-36.3% YoYEPS (Diluted)
-76.7% YoYTotal Assets
-36.5% YoYOp. Cash Flow
-130.9% YoYFree Cash Flow
-130.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Income | $-68.7M -31.0% | $-52.4M +13.2% | $-60.4M -134.9% | $-25.7M | — |
| Operating Income | $-75.2M -36.3% | $-55.2M +11.9% | $-62.6M -2241.5% | $-2.7M | — |
| EPS (Diluted) | $-1.06 -76.7% | $-0.60 +71.3% | $-2.09 +98.5% | $-141.97 | — |
| Total Assets | $113.9M -36.5% | $179.5M +78.0% | $100.8M +1816.4% | $5.3M -96.3% | $140.6M |
| Operating Cash Flow | $-64.8M -130.9% | $-28.1M -86.5% | $-15.1M -1305.6% | $-1.1M | — |
| Free Cash Flow | $-64.9M -130.6% | $-28.2M | — | — | — |
Get alerted when ZURA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Zura Bio Ltd including:
Top Institutional Holders of ZURA
SUVRETTA CAPITAL MANAGEMENT, LLC
$55.7M9,443,001 shVR Adviser, LLC
$38.0M6,434,990 shMPM BioImpact LLC
$26.4M4,472,843 shGREAT POINT PARTNERS LLC
$24.9M4,215,930 shJPMORGAN CHASE & CO
$24.5M4,354,715 shBRAIDWELL LP
$23.5M3,980,295 shSiren, L.L.C.
$22.0M3,734,866 shBlackRock, Inc.
$21.3M3,614,695 shCommodore Capital LP
$19.2M3,250,000 shADAGE CAPITAL PARTNERS GP, L.L.C.
$16.2M2,750,000 sh
| Fund | Value | Shares |
|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | $55.7M | 9,443,001 |
| VR Adviser, LLC | $38.0M | 6,434,990 |
| MPM BioImpact LLC | $26.4M | 4,472,843 |
| GREAT POINT PARTNERS LLC | $24.9M | 4,215,930 |
| JPMORGAN CHASE & CO | $24.5M | 4,354,715 |
| BRAIDWELL LP | $23.5M | 3,980,295 |
| Siren, L.L.C. | $22.0M | 3,734,866 |
| BlackRock, Inc. | $21.3M | 3,614,695 |
| Commodore Capital LP | $19.2M | 3,250,000 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $16.2M | 2,750,000 |
More Healthcare Companies
View all Healthcare →Put ZURA on your watchlist
Track score changes the day Zura Bio Ltd files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ZURA a good stock to buy?
13F Pro's AI-powered analysis of Zura Bio Ltd (ZURA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ZURA are available on the ZURA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ZURA is classified as a small company.
Which hedge funds own ZURA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ZURA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Zura Bio Ltd's investment landscape.